A medical news article previewing an international clinical trial report about a new drug’s effects on kidney disease and cardiovascular risks, inviting readers to learn what the study examines and why it matters.
Key Takeaways
- Trial found finerenone slowed estimated glomerular filtration rate decline in non‑diabetic CKD patients
- Finerenone reduced the risk of serious kidney outcomes and major cardiovascular events versus placebo
- Study enrolled an international cohort and reports results in the New England Journal of Medicine